FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders

Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase...

Descripció completa

Dades bibliogràfiques

Autors principals:	Austin Lui, Jordan Vanleuven, David Perekopskiy, Dewey Liu, Desiree Xu, Omar Alzayat, Taiseer Elgokhy, Timothy Do, Meghan Gann, Ryan Martin, Da-Zhi Liu
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-12-01
Col·lecció:	Pharmaceuticals
Matèries:	aberrant cell cycle disease cancers neurological disorders kinase inhibitors
Accés en línia:	https://www.mdpi.com/1424-8247/15/12/1546
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!